Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) announced that the company has been added to the Russell Global, Russell 3000®, Russell 2000®, and Russell Microcap ® Indexes on June 26, 2015.
“I am pleased by InVivo’s inclusion in the various Russell Indexes,” said Mark Perrin, InVivo’s CEO and Chairman. “The news comes less than three short months after our NASDAQ listing, and I’m happy to be executing on the long-term benefits of being NASDAQ-listed. We expect to see a significant increase in demand and liquidity from index funds looking to replicate the new Russell weightings, which will benefit our shareholders.” (Original Source)
Shares of Invivo Therapeutics Holdings Corp closed last Friday at $17.78. NVIV has a 1-year high of $19.68 and a 1-year low of $1.88. The stock’s 50-day moving average is $14.55 and its 200-day moving average is $10.57.
On the ratings front, H.C. Wainwright analyst Andrew Fein initiated coverage with a Buy rating on NVIV and a price target of $25, in a report issued on April 20. The current price target represents a potential upside of 41% from where the stock is currently trading. According to TipRanks.com, Fein has a total average return of 25.0%, a 68.1% success rate, and is ranked #107 out of 3681 analysts.
InVivo Therapeutics Holdings Corp is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries.